Table 2.
Mean estimated case-weighted measles case–fatality ratio for a no-vaccination scenario, by year, setting, and region
|
1990 |
2000 |
2010 |
2019 |
|||||
|---|---|---|---|---|---|---|---|---|
| Community-based | Hospital-based | Community-based | Hospital-based | Community-based | Hospital-based | Community-based | Hospital-based | |
| All locations | 4·06% (3·84–4·29) | 15·15% (14·43–15·94) | 3·17% (2·99–3·36) | 12·05% (11·45–12·77) | 2·34% (2·19–2·51) | 9·20% (8·65–9·84) | 2·08% (1·94–2·23) | 8·24% (7·75–8·86) |
| North Africa and the Middle East | 5·04% (4·66–5·48) | 18·26% (17·03–19·65) | 4·51%4·19–4·90) | 16·45% (15·39–17·67) | 3·52% (3·25–3·82) | 13·25% (12·33–14·29) | 1·83% (1·68–1·99) | 7·19% (6·65–7·79) |
| Sub-Saharan Africa | 5·32% (5·04–5·62) | 19·03% (18·30–19·87) | 4·15% (3·93–4·41) | 15·41% (14·73–16·17) | 3·67% (3·46–3·92) | 13·79% (13·07–14·65) | 2·77% (2·59–2·96) | 10·77% (10·16–11·51) |
| Central Europe, eastern Europe, and central Asia | 1·97% (1·78–2·14) | 7·97% (7·31–8·61) | 0·56% (0·50–0·63) | 2·39% (2·14–2·67) | 0·37% (0·33–0·42) | 1·57% (1·39–1·77) | 0·33% (0·29–0·38) | 1·42% (1·25–1·62) |
| South Asia | 4·50% (4·25–4·76) | 16·88% (16·03–17·79) | 3·42% (3·20–3·65) | 13·21% (12·46–14·05) | 2·49% (2·31–2·67) | 9·89% (9·25–10·63) | 1·61% (1·49–1·74) | 6·57% (6·11–7·11) |
| Latin America | 2·75% (2·48–3·01) | 10·80% (9·84–11·84) | 1·88% (1·68–2·07) | 7·58% (6·81–8·41) | 1·24% (1·08–1·40) | 5·12% (4·50–5·75) | 0·88% (0·77–1·01) | 3·66% (3·18–4·16) |
| Southeast Asia, east Asia, and Oceania | 1·64% (1·52–1·78) | 6·68% (6·21–7·21) | 1·16% (1·06–1·26) | 4·79% (4·40–5·21) | 0·83% (0·75–0·91) | 3·45% (3·13–3·79) | 0·75% (0·68–0·83) | 3·15% (2·86–3·47) |
Data are % (95% uncertainty interval).